Medifast, Inc.
MED
$13.40
$0.211.59%
NYSE
06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
---|---|---|---|---|---|
Revenue | -37.62% | -39.47% | -43.80% | -44.64% | -43.90% |
Total Other Revenue | -- | -- | -- | -- | -- |
Total Revenue | -37.62% | -39.47% | -43.80% | -44.64% | -43.90% |
Cost of Revenue | -37.39% | -41.14% | -46.71% | -47.72% | -48.15% |
Gross Profit | -37.70% | -38.85% | -42.69% | -43.45% | -42.23% |
SG&A Expenses | -34.08% | -29.39% | -32.19% | -32.34% | -33.35% |
Depreciation & Amortization | -- | -- | -- | -- | -- |
Other Operating Expenses | -- | -- | -- | -- | -- |
Total Operating Expenses | -34.78% | -32.71% | -36.60% | -37.14% | -38.03% |
Operating Income | -98.58% | -107.82% | -97.72% | -93.33% | -81.50% |
Income Before Tax | -83.23% | -108.35% | -97.06% | -91.87% | -78.41% |
Income Tax Expenses | -67.13% | -101.43% | -94.23% | -84.16% | -80.01% |
Earnings from Continuing Operations | -87.60% | -110.32% | -97.90% | -93.89% | -77.94% |
Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
Minority Interest in Earnings | -- | -- | -- | -- | -- |
Net Income | -87.60% | -110.32% | -97.90% | -93.89% | -77.94% |
EBIT | -98.58% | -107.82% | -97.72% | -93.33% | -81.50% |
EBITDA | -57.13% | -86.72% | -84.45% | -88.22% | -76.01% |
EPS Basic | -87.70% | -110.28% | -97.89% | -93.88% | -77.89% |
Normalized Basic EPS | -83.34% | -108.32% | -97.05% | -92.46% | -79.80% |
EPS Diluted | -88.07% | -110.50% | -98.02% | -94.02% | -77.91% |
Normalized Diluted EPS | -83.33% | -108.36% | -97.09% | -92.49% | -79.80% |
Average Basic Shares Outstanding | 0.42% | 0.41% | 0.42% | 0.27% | 0.00% |
Average Diluted Shares Outstanding | 0.45% | 0.22% | 0.38% | 0.13% | -0.20% |
Dividend Per Share | -- | -- | -- | -100.00% | -74.92% |
Payout Ratio | -0.96% | -1.04% | -0.53% | 3.19% | 1.28% |